The article "Dyslipidaemia management in pregnant patients: a 2024 update" by Joanna Lewek, Agata Bielecka-Dąbrowa, Peter P. Toth, and Maciej Banach provides an overview of the challenges and recent advancements in managing dyslipidaemia during pregnancy. The authors highlight that while there has been little progress in clinical trials involving pregnant patients, behavioral modifications, pre-conception management, and careful clinical assessment are crucial. Bile acid sequestrants are the only lipid-lowering medications officially approved for pregnancy, while ezetimibe and fenofibrate can be considered if their benefits outweigh potential risks. Statins are generally contraindicated due to concerns about teratogenicity and adverse birth outcomes, although recent studies suggest they may be safe for high-risk patients with severe familial hypercholesterolaemia (FH). Omega-3 fatty acids and lipoprotein apheresis are also discussed as potential options. The article emphasizes the need for personalized treatment decisions and the importance of monitoring and managing dyslipidaemia to prevent adverse outcomes for both the mother and the fetus. Despite the challenges, the authors advocate for more research to establish the safety and efficacy of dyslipidaemia treatments during pregnancy.The article "Dyslipidaemia management in pregnant patients: a 2024 update" by Joanna Lewek, Agata Bielecka-Dąbrowa, Peter P. Toth, and Maciej Banach provides an overview of the challenges and recent advancements in managing dyslipidaemia during pregnancy. The authors highlight that while there has been little progress in clinical trials involving pregnant patients, behavioral modifications, pre-conception management, and careful clinical assessment are crucial. Bile acid sequestrants are the only lipid-lowering medications officially approved for pregnancy, while ezetimibe and fenofibrate can be considered if their benefits outweigh potential risks. Statins are generally contraindicated due to concerns about teratogenicity and adverse birth outcomes, although recent studies suggest they may be safe for high-risk patients with severe familial hypercholesterolaemia (FH). Omega-3 fatty acids and lipoprotein apheresis are also discussed as potential options. The article emphasizes the need for personalized treatment decisions and the importance of monitoring and managing dyslipidaemia to prevent adverse outcomes for both the mother and the fetus. Despite the challenges, the authors advocate for more research to establish the safety and efficacy of dyslipidaemia treatments during pregnancy.